Serum Free Light Change in Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by:
Azienda Ospedaliera San Giovanni Battista
ClinicalTrials.gov Identifier:
NCT00910078
First received: May 28, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted
  Purpose

The purpose of this study is to evaluate the predictive role of free Kappa/Lambda ration in Multiple Myeloma post-transplant.


Condition
Multiple Myeloma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Serum Free Light Chain Ratio, Total Kappa/Lambda Ratio, and Immunofixation as Prognostic Factors in Multiple Myeloma.

Resource links provided by NLM:


Further study details as provided by Azienda Ospedaliera San Giovanni Battista:

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

A cohort of patients undergoing autolog transplantatio

Criteria

Inclusion Criteria:

  • Patients affected with Multiple Myeloma who underwent autologous or auto/allogenic stem cell transplantation.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00910078

Locations
Italy
Azienda Ospedaliera S. Giovanni Battista
Torino, Italy, 10126
Sponsors and Collaborators
Azienda Ospedaliera San Giovanni Battista
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00910078     History of Changes
Other Study ID Numbers: sFLC r, KLR and IFIX
Study First Received: May 28, 2009
Last Updated: May 28, 2009
Health Authority: Italy: Ministry of Health

Keywords provided by Azienda Ospedaliera San Giovanni Battista:
Total kappa and lambda ratio
Stem cell transplantation
Serum immunofixation

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on April 17, 2014